Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

LITAK 2mg/ml solution for injection

Active Ingredient:
cladribine
Company:  
LIPOMED GmbH See contact details
ATC code: 
L01BB04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

DHPC for Cladribine (Litak and Leustat), 01 Dec 2017

{healthcare_pro_orange} For Healthcare Professionals
Risk of progressive multifocal leukoencephalopathy (PML)

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

LIPOMED GmbH
Company image
Address
Hegenheimer Strasse 2, 79576 Weil am Rhein, Germany
Telephone
+49 7621 1693 473
Fax
+49 7621 1693474
E-mail
[email protected]
Medical Information Direct Line
+41 61 702 02 00
Medical Information Fax
+41 61 702 02 20
Medical Information e-mail
[email protected]
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0) 7395 177229
WWW
http://www.lipomed.com